HOUSTON - Bio-Path Holdings, Inc. (NASDAQ:BPTH), a biotechnology company with a market capitalization of $3.1 million, has announced continued progress in its clinical trials for cancer treatments.

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...

Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...

(AML) patients across both original and expansion cohorts remain in complete remission (CR), with a median follow-up of 20.1 months AML patients treated demonstrated one-year ...